CV
Central Retinal Vein Occlusion
search
Central Retinal Vein Occlusion
, CRVO
See Also
Central Retinal Artery Occlusion
Epidemiology
Common cause of
Vision Loss
in older adults
However, also common in young adults (one third of cases in age <45 years old)
Contrast with
Central Retinal Artery Occlusion
in older adults
Pathophysiology
Venous
Occlusion
results in
Retina
l edema,
Hemorrhage
and vascular leak
Venous Thromboembolism
may result from vessel damage or
Hypercoagulable
state
Risk Factors
Hypercoagulable
State
Age over 55 years
Hypertension
Hyperlipidemia
Diabetes Mellitus
Tobacco Abuse
Types
Nonischemic Central Retinal Vein Occlusion (75% of cases)
Progresses to ischemic types in 15% of patients within 4 months (34% within 3 years)
Sudden painless, unilateral visual blurring (better than 20/200)
Mild funduscopic findings
No
Relative Afferent Pupillary Defect
Ischemic Central Retinal Vein Occlusion
Sudden painless, severe unilateral visual loss (worse than 20/200)
Relative Afferent Pupillary Defect
Marked funduscopic changes
Symptoms
Monocular painless visual loss
May initially present with transient episodes of mild
Blurred Vision
Signs
Decreased Visual Acuity
Non-ischemic CRVO:
Vision
better than 20/200
Ischemic CRVO:
Vision
worse than 20/200
Afferent Pupillary Defect
may be present (esp. ischemic CRVO)
Funduscopic Exam
Retina
l veins dilated and tortuous
Blood streaked
Retina
or flame-shaped
Hemorrhage
s (esp. in ischemic type)
Diffuse
Retina
l
Hemorrhage
s radiating from optic disc ("Blood and thunder
Retina
")
Cotton wool patches may be present (esp. with
Hypertension
)
Differential Diagnosis
See
Acute Vision Loss
Optic Neuritis
Central Retinal Artery Occlusion
Management
Urgent Ophthalmology
Consultation
Antivascular endothelial growth factors
Corticosteroid
s
Photocoagulation (if neovascularization)
No specific management to alter
Hemorrhage
s
Management is focused on reducing longerterm complications of
Retinopathy
including
Glaucoma
Non-urgent laser photocoagulation may be needed in some cases
Management is also focused on reducing risk of disease progression
Optimize management of
Hypertension
and
Diabetes Mellitus
Optimize hydration
Decrease
Intraocular Pressure
(e.g.
Acetazolamide
)
Patient Instructions
Return immediately for
Decreased Visual Acuity
Follow-up after initial ophthalmology evaluations
Follow-up ophthalmology in 3 months (monthly for at least 6 months if ischemic CRVO)
Prognosis
For those who do not convert to ischemic CRVO, 50% will recover nearly normal
Vision
Complications
Vision Loss
Glaucoma
References
Hartmann (2016) Crit Dec Emerg Med 30(6): 3-11
Sales, Patel and Patel (2019) Crit Dec Emerg Med 33(12): 3-13
Type your search phrase here